Cargando…

Takotsubo cardiomyopathy in cancer patients

BACKGROUND: Cancer is a chronic condition that induces significant emotional and physical stress, which may increase the risk for developing Takotsubo cardiomyopathy (TCM). MAIN BODY: Takotsubo cardiomyopathy, also known as stress cardiomyopathy, is a clinical syndrome that generally presents as che...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Aakash, Noor, Arish, Joshi, Saurabh, Kim, Agnes S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048040/
https://www.ncbi.nlm.nih.gov/pubmed/32154014
http://dx.doi.org/10.1186/s40959-019-0042-9
_version_ 1783502226264686592
author Desai, Aakash
Noor, Arish
Joshi, Saurabh
Kim, Agnes S.
author_facet Desai, Aakash
Noor, Arish
Joshi, Saurabh
Kim, Agnes S.
author_sort Desai, Aakash
collection PubMed
description BACKGROUND: Cancer is a chronic condition that induces significant emotional and physical stress, which may increase the risk for developing Takotsubo cardiomyopathy (TCM). MAIN BODY: Takotsubo cardiomyopathy, also known as stress cardiomyopathy, is a clinical syndrome that generally presents as chest pain mimicking acute coronary syndrome or as an acute heart failure characterized by severe left ventricular systolic dysfunction in response to emotional, physical, or medical stress. The potential triggers for Takotsubo syndrome in cancer patients include the emotional turmoil of a cancer diagnosis, the inflammatory state of the cancer itself, and the physical stress of cancer surgery, systemic anti-neoplastic therapy, and radiation treatment. TCM is becoming increasingly recognized among patients with cancer and has been associated with adverse outcomes in this patient population. In this study, we searched the Pubmed database using keywords “Takotsubo cardiomyopathy”, “cancer”, and “anti-neoplastic therapy” to review case reports of Takotsubo syndrome occurring in oncologic patients after systemic anti-neoplastic therapy. Clinical presentation, electrocardiogram, laboratory data, transthoracic echocardiogram and coronary angiogram results, and patient outcomes were collected and analyzed. CONCLUSION: Patients with cancer are at an elevated risk for developing stress cardiomyopathy, and it is important to know which cancer drugs have been associated with the development of the Takotsubo syndrome.
format Online
Article
Text
id pubmed-7048040
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70480402020-03-09 Takotsubo cardiomyopathy in cancer patients Desai, Aakash Noor, Arish Joshi, Saurabh Kim, Agnes S. Cardiooncology Review BACKGROUND: Cancer is a chronic condition that induces significant emotional and physical stress, which may increase the risk for developing Takotsubo cardiomyopathy (TCM). MAIN BODY: Takotsubo cardiomyopathy, also known as stress cardiomyopathy, is a clinical syndrome that generally presents as chest pain mimicking acute coronary syndrome or as an acute heart failure characterized by severe left ventricular systolic dysfunction in response to emotional, physical, or medical stress. The potential triggers for Takotsubo syndrome in cancer patients include the emotional turmoil of a cancer diagnosis, the inflammatory state of the cancer itself, and the physical stress of cancer surgery, systemic anti-neoplastic therapy, and radiation treatment. TCM is becoming increasingly recognized among patients with cancer and has been associated with adverse outcomes in this patient population. In this study, we searched the Pubmed database using keywords “Takotsubo cardiomyopathy”, “cancer”, and “anti-neoplastic therapy” to review case reports of Takotsubo syndrome occurring in oncologic patients after systemic anti-neoplastic therapy. Clinical presentation, electrocardiogram, laboratory data, transthoracic echocardiogram and coronary angiogram results, and patient outcomes were collected and analyzed. CONCLUSION: Patients with cancer are at an elevated risk for developing stress cardiomyopathy, and it is important to know which cancer drugs have been associated with the development of the Takotsubo syndrome. BioMed Central 2019-07-01 /pmc/articles/PMC7048040/ /pubmed/32154014 http://dx.doi.org/10.1186/s40959-019-0042-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Desai, Aakash
Noor, Arish
Joshi, Saurabh
Kim, Agnes S.
Takotsubo cardiomyopathy in cancer patients
title Takotsubo cardiomyopathy in cancer patients
title_full Takotsubo cardiomyopathy in cancer patients
title_fullStr Takotsubo cardiomyopathy in cancer patients
title_full_unstemmed Takotsubo cardiomyopathy in cancer patients
title_short Takotsubo cardiomyopathy in cancer patients
title_sort takotsubo cardiomyopathy in cancer patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048040/
https://www.ncbi.nlm.nih.gov/pubmed/32154014
http://dx.doi.org/10.1186/s40959-019-0042-9
work_keys_str_mv AT desaiaakash takotsubocardiomyopathyincancerpatients
AT noorarish takotsubocardiomyopathyincancerpatients
AT joshisaurabh takotsubocardiomyopathyincancerpatients
AT kimagness takotsubocardiomyopathyincancerpatients